Dr. Trabulsi on Clinical Trial Combination Approaches in Prostate Cancer

Edouard J. Trabulsi, MD
Published: Wednesday, Mar 28, 2018



Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

The CALGB PUNCH (Preoperative Use of Neoadjuvant ChemoHormonal Therapy) trial enrolled high-risk patients who received preoperative hormonal therapy and chemotherapy followed by surgery. The trial began approximately 10 years ago, before the recent explosion of interest in cytotoxic chemotherapy for early-stage prostate cancer, as seen in the docetaxel CHAARTED and STAMPEDE trials. It overlaps nicely with that data, says Trabulsi.

Sidney Kimmel Cancer Center did an institutional trial with Robert B. Den, MD, investigating the use of cabazitaxel in combination with hormonal and radiotherapy in high-risk patients on standard radiotherapy. That may turn into a much larger trial, he says.
 


Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, discusses clinical trials that are investigating combination approaches for patients with prostate cancer.

The CALGB PUNCH (Preoperative Use of Neoadjuvant ChemoHormonal Therapy) trial enrolled high-risk patients who received preoperative hormonal therapy and chemotherapy followed by surgery. The trial began approximately 10 years ago, before the recent explosion of interest in cytotoxic chemotherapy for early-stage prostate cancer, as seen in the docetaxel CHAARTED and STAMPEDE trials. It overlaps nicely with that data, says Trabulsi.

Sidney Kimmel Cancer Center did an institutional trial with Robert B. Den, MD, investigating the use of cabazitaxel in combination with hormonal and radiotherapy in high-risk patients on standard radiotherapy. That may turn into a much larger trial, he says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x